Lilly pips Pfizer to the big pharma top spot on share price performance, while Covid-19 drives the largest risers elsewhere.
A handful of huge success stories mask disappointing performances elsewhere, with small caps and Asian pharma firms feeling the pain.
Can a trial carried out in China back a US approval? Investors in anti-PD-(L)1 players will find out soon enough.
Investors nursing a fall in biotech indices now have to digest the failure of Bridgebio's acoramidis in 2021’s last important catalyst.
Important breast cancer data will come in the opening months of 2022, and Glaxo and Pfizer are due pivotal RSV results.
Sanofi’s latest acquisition sees the group pay $1bn for the private immuno-oncology company Amunix.
Explore what might be in store for biopharma next year in our new report, with new data analyses, catalyst tables and investor interviews.